Researchers at the Japanese National Cancer Center Research Institute have identified an "epigenetic reconditioning" approach that could force liver cancer cells to differentiate, rendering them less aggressive. Epigenetic changes are a frequent feature of liver tumors, which have few therapeutic options.

Scientists at the Johns Hopkins Medical School have demonstrated that the experimental glucagon-like peptide 1 (GLP-1) receptor agonist NLY-01 (Neuraly Inc.) was protective against Parkinson's disease (PD) in two separate mouse models.

Innate immune system activation appears to be linked to late-onset Alzheimer's disease (AD), which has led to speculation that infections might play a role in AD risk. Now, a team from the Mount Sinai School of Medicine has shown that individuals with AD had high levels of two separate herpes viruses in their brain. 

Researchers from the RV411 study group have reported that even when HIV-infected individuals started antiretroviral treatment (ART) within two weeks of infection, it could not prevent the establishment of a viral reservoir nor the occurrence of viral rebound if treatment was interrupted. 

Researchers at the University of Washington have used information from acquired mutations in mismatch repair genes to assess whether the same mutations, when they occurred in the germline, put those that harbored them at risk of Lynch syndrome.

Birds do it. Bees do it. "Even jellyfish have this need," Qinghua Liu told BioWorld. Liu was referring, of course, to sleep, which he called "essentially... a black box, and one of the biggest mysteries of brain science."

ATLANTA – In the search for good antibacterial targets, new sites on validated structures are one sweet spot. Because they are on previously targeted structures, they are in principle validated targets. At the same time, targeting novel sites can turn back the clock in the antibiotic resistance race, particularly if there is no cross-resistance with existing antibiotics that target the same structure.